SEARCH

SEARCH BY CITATION

References

  • Aaronson, N.K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N.J., Filiberti, A., Flechtner, H., Fleishman, S.B. & De Haes, J.C. (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85, 365376.
  • American Society of Clinical Oncology (1996) Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. Journal of Clinical Oncology, 14, 671679.
  • Attal, M., Harousseau, J.L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., Voillat, L., Sotto, J.J., Grosbois, B. & Bataille, R. (2003) Single versus double autologous stem-cell transplantation for multiple myeloma. New England Journal of Medicine, 349, 24952502.
  • Barlogie, B., Kyle, R.A., Anderson, K.C., Greipp, P.R., Lazarus, H.M., Hurd, D.D., McCoy, J., Dakhil, S.R., Lanier, K.S., Chapman, R.A., Cromer, J.N., Salmon, S.E., Durie, B. & Crowley, J.C. (2006) Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. Journal of Clinical Oncology, 24, 929936.
  • Browall, M., Ahlberg, K., Karlsson, P., Danielson, E., Persson, L.O. & Gaston-Johansson, F. (2008) Health-related quality of life during adjuvant treatment for breast cancer among postmenopausal women. European Journal of Oncology Nursing, 12, 180189.
  • Calhoun, E.A., Fishman, D.A., Roland, P.Y., Lurain, J.R., Chang, C. & Cella, D. (2000) Validity and selective sensitivity of the FACT-GOG Ntx. Journal of Clinical Oncology, 19, 446a.
  • Calhoun, E.A., Welshman, E.E., Chang, C.H., Lurain, J.R., Fishman, D.A., Hunt, T.L. & Cella, D. (2003) Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. International Journal of Gynecological Cancer, 13, 741748.
  • Child, J.A., Morgan, G.J., Davies, F.E., Owen, R.G., Bell, S.E., Hawkins, K., Brown, J., Drayson, M.T. & Selby, P.J. (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. New England Journal of Medicine, 348, 18751883.
  • Dubois, D., Dhawan, R., Van De Velde, H., Esseltine, D., Gupta, S., Viala, M. & De La Loge, C. (2006) Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma. Journal of Clinical Oncology, 24, 976982.
  • Dvorak, C. (2006) Common complaints, difficult diagnosis: multiple myeloma. Journal of the American Academy of Nurse Practitioners, 18, 190194.
  • Facon, T., Mary, J.Y., Hulin, C., Benboubker, L., Attal, M., Pegourie, B., Renaud, M., Harousseau, J.L., Guillerm, G., Chaleteix, C., Dib, M., Voillat, L., Maisonneuve, H., Troncy, J., Dorvaux, V., Monconduit, M., Martin, C., Casassus, P., Jaubert, J., Jardel, H., Doyen, C., Kolb, B., Anglaret, B., Grosbois, B., Yakoub-Agha, I., Mathiot, C. & Vet-Loiseau, H. (2007) Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet, 370, 12091218.
  • Fayers, P.M., Aaronson, N., Bjordal, K., Curran, D. & Groenvold, M. (1999) The EORTC QLQ-C30 Scoring Manual, 2nd edn. European Organisation for Research and Treatment of Cancer, Brussels.
  • Fermand, J.P., Katsahian, S., Divine, M., Leblond, V., Dreyfus, F., Macro, M., Arnulf, B., Royer, B., Mariette, X., Pertuiset, E., Belanger, C., Janvier, M., Chevret, S., Brouet, J.C. & Ravaud, P. (2005) High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. Journal of Clinical Oncology, 23, 92279233.
  • Gotay, C.C., Kawamoto, C.T., Bottomley, A. & Efficace, F. (2008) The prognostic significance of patient-reported outcomes in cancer clinical trials. Journal of Clinical Oncology, 26, 13551363.
  • Gulbrandsen, N., Wisloff, F., Brinch, L., Carlson, K., Dahl, I.M., Gimsing, P., Hippe, E., Hjorth, M., Knudsen, L.M., Lamvik, J., Lenhoff, S., Lofvenberg, E., Nesthus, I., Nielsen, J.L., Turesson, I. & Westin, J. (2001) Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support. Medical Oncology, 18, 6577.
  • Gulbrandsen, N., Hjermstad, M.J. & Wisloff, F. (2004) Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences. European Journal of Haematology, 72, 172180.
  • Hedenus, M., Adriansson, M., San, M.J., Kramer, M.H., Schipperus, M.R., Juvonen, E., Taylor, K., Belch, A., Altes, A., Martinelli, G., Watson, D., Matcham, J., Rossi, G. & Littlewood, T.J. (2003) Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. British Journal Haematology, 122, 394403.
  • Hjermstad, M.J., Fossa, S.D., Bjordal, K. & Kaasa, S. (1995) Test/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire. Journal of Clinical Oncology, 13, 12491254.
  • Hochberg, Y. (1988) A sharper Bonferroni procedure for multiple tests of significance. Biometrika, 75, 800802.
  • Huang, H.Q., Brady, M.F., Cella, D. & Fleming, G. (2007) Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. Int J Gynecol Cancer, 17, 387393.
  • Hulin, C., Facon, T., Rodon, P., Pegourie, B., Benboubker, L., Doyen, C., Dib, M., Guillerm, G., Voillat, L., Mathiot, C., Casassus, P., Decaux, O., Flesch, M., Garderet, L. & Moreau, P. (2007) Melphalan-prednisone-thalidomide (MP-T) demonstrates a significant survival advantage in elderly patients 75 years with multiple myeloma compared with melphalan-prednisone (MP) in a randomized, double-blind, placebo-controlled trial, IFM 01/01. Blood, 110, 31a.
  • Kaasa, S., Bjordal, K., Aaronson, N., Moum, T., Wist, E., Hagen, S. & Kvikstad, A. (1995) The EORTC core quality of life questionnaire (QLQ-C30): validity and reliability when analysed with patients treated with palliative radiotherapy. European Journal of Cancer, 31A, 22602263.
  • Kane, R.C., Farrell, A.T., Sridhara, R. & Pazdur, R. (2006) United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clinical Cancer Research, 12, 29552960.
  • Kumar, S.K., Rajkumar, S.V., Dispenzieri, A., Lacy, M.Q., Hayman, S.R., Buadi, F.K., Zeldenrust, S.R., Dingli, D., Russell, S.J., Lust, J.A., Greipp, P.R., Kyle, R.A. & Gertz, M.A. (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood, 111, 25162520.
  • Kyle, R.A., Gertz, M.A., Witzig, T.E., Lust, J.A., Lacy, M.Q., Dispenzieri, A., Fonseca, R., Rajkumar, S.V., Offord, J.R., Larson, D.R., Plevak, M.E., Therneau, T.M. & Greipp, P.R. (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proceedings, 78, 2133.
  • Lee, S., Richardson, P.G., Barlogie, B., Berenson, J.R., Singhal, S., Jagannath, S., Irwin, D., Schenkein, D. & Anderson, K.C. (2003) Quality-of-life (QOL) and clinical benefit assessment in patients with relapsed and refractory multiple myeloma (MM) treated with bortezomib. Journal of Clinical Oncology, 22, 582s.
  • Little, R.J.A. & Rubin, D.B. (1987) Statisical Analysis with MissingData, 1st edn. Wiley and Sons, Hoboken, New Jersey.
  • McKernan, M., McMillan, D.C., Anderson, J.R., Angerson, W.J. & Stuart, R.C. (2008) The relationship between quality of life (EORTC QLQ-C30) and survival in patients with gastro-oesophageal cancer. British Journal of Cancer, 98, 888893.
  • Michiels, B., Molenberghs, G., Bijnens, L., Vangeneugden, T. & Thijs, H. (2002) Selection models and pattern-mixture models to analyse longitudinal quality of life data subject to drop-out. Statistics in Medicine, 21, 10231041.
  • Osterborg, A., Brandberg, Y., Molostova, V., Iosava, G., Abdulkadyrov, K., Hedenus, M. & Messinger, D. (2002) Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. Journal of Clinical Oncology, 20, 24862494.
  • Rajkumar, S.V., Jacobus, S., Callander, N., Fonseca, R., Vesole, D., Williams, M., Abonour, R., Siegel, D. & Greipp, P. (2007) A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. Blood, 110, 31a.
  • Richardson, P.G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S.V., Srkalovic, G., Alsina, M., Alexanian, R., Siegel, D., Orlowski, R.Z., Kuter, D., Limentani, S.A., Lee, S., Hideshima, T., Esseltine, D.L., Kauffman, M., Adams, J., Schenkein, D.P. & Anderson, K.C. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. New England Journal of Medicine, 348, 26092617.
  • Richardson, P.G., Sonneveld, P., Schuster, M.W., Irwin, D., Stadtmauer, E.A., Facon, T., Harousseau, J.L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., San-Miguel, J.F., Blade, J., Boccadoro, M., Cavenagh, J., Dalton, W.S., Boral, A.L., Esseltine, D.L., Porter, J.B., Schenkein, D. & Anderson, K.C. (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. New England Journal of Medicine, 352, 24872498.
  • Richardson, P.G., Sonneveld, P., Schuster, M., Irwin, D., Stadtmauer, E., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., San Miguel, J., Bladé, J., Boccadoro, M., Cavenagh, J., Alsina, M., Rajkumar, S.V., Lacy, M., Jakubowiak, A., Dalton, W., Boral, A., Esseltine, D.-L., Schenkein, D. & Anderson, K. (2007) Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood, 110, 35573560.
  • San Miguel, J.F., Richardson, P., Sonneveld, P., Schuster, M., Irwin, D., Stadtmauer, E., Facon, T., Harousseau, J., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., Blade, J., Boccadoro, M., Cavenagh, J., Dalton, W., Boral, A., Schenkein, D. & Anderson, K. (2005) Frequency, characteristics, and reversibility of peripheral neuropathy (PN) in the APEX trial. Blood, 106, 111a.
  • Sun, J. & Song, P.X. (2001) Statistical analysis of repeated measurements with informative censoring times. Statistics in Medicine, 20, 6373.
  • Uyl-de Groot, C.A., Buijt, I., Gloudemans, I.J., Ossenkoppele, G.J., Berg, H.P. & Huijgens, P.C. (2005) Health related quality of life in patients with multiple myeloma undergoing a double transplantation. European Journal of Haematology, 74, 136143.
  • Viala, M., Bhakar, A.L., De La Loge, C., Van De Velde, H., Esseltine, D., Chang, M., Dhawan, R. & Dubois, D. (2007) Patient-reported outcomes helped predict survival in multiple myeloma using partial least squares analysis. Journal of Clinical Epidemiology, 60, 670679.
  • Westfall, P., Tobias, R., Rom, D., Wolfinger, R.D. & Hochberg, Y. (1999) Multiple Comparisons and Multiple Tests Using the SAS System, 1st edn. SAS Institute, Cary, NC.
  • Wisløff, F. & Hjorth, M. (1997) Health-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma. Nordic Myeloma Study Group. British Journal Haematology, 97, 2937.
  • Wisløff, F., Eika, S., Hippe, E., Hjorth, M., Holmberg, E., Kaasa, S., Palva, I. & Westin, J. (1996) Measurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group. British Journal Haematology, 92, 604613.
  • Wittes, R.E. (1987) Antineoplastic agents and FDA regulations: square pegs for round holes? Cancer Treatment Reports, 71, 795806.
  • Zeger, S.L., Liang, K.Y. & Albert, P.S. (1988) Models for longitudinal data: a generalized estimating equation approach. Biometrics, 44, 10491060.